CRISPR Therapeutics AG

**SIGNAL NOTE: EcoR1 Capital initiates $72.9M position in CRSP** EcoR1's entry signals conviction in CRISPR's clinical pipeline momentum, likely driven by near-term catalysts around CTX001 (ex vivo CRISPR for sickle cell/beta-thalassemia) regulatory decisions or label expansion data expected in 2024-25. The $72.9M position size suggests a growth-stage crossover thesis on margin expansion as ex vivo therapies scale, though execution risk remains material given CRISPR's historical manufacturing challenges and competition from base-edited rivals (BEAM, VERV).